 |
|
|
| |
Treatment with a TLR7 Agonist Induces Transient Viremia in SIV-Infected ART-Suppressed Monkeys
|
| |
| |
Reported by Jules Levin
CROI 2015 Feb 23-26, Seattle, WA
James Whitney, Ph.D.
Center for Virology and Vaccine Research
Beth Israel Deaconess Medical Center
Ragon Institute of MGH, MIT and Harvard
Harvard Medical School
Preclinical Characterization of GS-9620, A Potent and Selective Oral TLR7 Agonist......http://www.natap.org/2011/EASL/EASL_57.htm
GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus (and HCV) in Chronically Infected Chimpanzees......http://www.natap.org/2013/HBV/021913_02.htm
Targeting Innate HBV Immunity: A New Step in the Development of Combination Therapy for Chronic Hepatitis B; GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees......http://www.natap.org/2013/HBV/062613_01.htm
Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees.....http://www.natap.org/2011/EASL/EASL_72.htm
|
| |
|
|
|
|
|
